Holen Sie sich die Stockscreener-App
82.14
5.93%
4.60
Handel nachbörslich:
82.14
Schlusskurs vom Vortag:
$77.54
Offen:
$77.38
24-Stunden-Volumen:
327.37K
Relative Volume:
0.58
Marktkapitalisierung:
$3.10B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-91.00M
KGV:
-22.38
EPS:
-3.67
Netto-Cashflow:
$-74.38M
1W Leistung:
+11.00%
1M Leistung:
+2.25%
6M Leistung:
+35.52%
1J Leistung:
+46.78%
1-Tages-Spanne:
$77.33
$82.26
1-Wochen-Bereich:
$73.77
$82.26
52-Wochen-Spanne:
$30.82
$99.50
Disc Medicine Inc Stock (IRON) Company Profile
Firmenname
Disc Medicine Inc
Sektor
Branche
Telefon
(617) 674-9274
Adresse
321 ARSENAL STREET, SUITE 101, WATERTOWN
Vergleichen Sie IRON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IRON
Disc Medicine Inc
|
82.14 | 2.93B | 0 | -91.00M | -74.38M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Disc Medicine Inc Stock (IRON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-03 | Fortgesetzt | Stifel | Buy |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-06-11 | Fortgesetzt | Raymond James | Strong Buy |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-11-04 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-10-23 | Eingeleitet | Jefferies | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-22 | Eingeleitet | Wells Fargo | Overweight |
| 2024-04-01 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2023-06-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2023-06-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-05-17 | Eingeleitet | Raymond James | Outperform |
| 2023-04-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-04-21 | Eingeleitet | Stifel | Buy |
| 2023-04-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-03-23 | Eingeleitet | BMO Capital Markets | Outperform |
| 2023-02-28 | Eingeleitet | SVB Securities | Outperform |
Alle ansehen
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst - streetwisereports.com
Pomerantz LLP Investigates Securities Fraud Claims Against Disc Medicine - Intellectia AI
Bear Alert: What is Disc Medicine Inc. s debt to equity ratioJuly 2025 Catalysts & Accurate Intraday Trade Tips - baoquankhu1.vn
HC Wainwright Weighs in on Disc Medicine FY2030 Earnings - MarketBeat
Disc Medicine and Sanofi reportedly face delays for FDA national priority review vouchers - MSN
iA Global Asset Management Inc. Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Understanding the Setup: (IRON) and Scalable Risk - Stock Traders Daily
Disc Medicine (NASDAQ:IRON) Insider Rahul Khara Sells 1,000 Shares of Stock - MarketBeat
The Bull Case For Disc Medicine (IRON) Could Change Following FDA Review Delay And New HR Chief Appointment - Sahm
Disc Medicine, Sanofi, Eli Lilly Shares Slip On Reports Of FDA Increasing Review Time For Drugs Granted Priority Review Vouchers - Stocktwits
Is Disc Medicine Inc. attractive at current valuationWeekly Market Outlook & High Win Rate Trade Alerts - bollywoodhelpline.com
Assessing Disc Medicine (IRON) Valuation After FDA Review Delay And Heightened Regulatory Focus - Sahm
Analysts Offer Insights on Healthcare Companies: CG Oncology, Inc. (CGON) and Disc Medicine (IRON) - The Globe and Mail
Short Interest in Disc Medicine, Inc. (NASDAQ:IRON) Grows By 53.8% - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Disc Medicine Analyst Remains Confident In Rare Disease Drug Despite FDA ActionDisc Medicine (NASDAQ:IRON) - Benzinga
Disc Medicine (IRON) Valuation Check As Bitopertin Wins Priority FDA Review And Commercial Plans Advance - Yahoo Finance
Reported delays to FDA reviews under new fast-track program - The Pharma Letter
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
FDA Shows Caution, Delays Trump-Backed Fast-Track Drugs Over Risks (UPDATED) - Benzinga
Klein Hersh Recruits CHRO for Disc Medicine - Hunt Scanlon Media
Disc Medicine (IRON) Stock Declines Amid Market Movement - GuruFocus
What Investors Should Know About a $511K Disc Medicine Insider Sale and a 26% Stock Run - AOL.com
Exclusive: US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - Reuters
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns - TradingView — Track All Markets
Disc Medicine (IRON) Faces Review Delay for Rare Disease Drug - GuruFocus
Disc Medicine stock rating reiterated by Morgan Stanley amid FDA review - Investing.com South Africa
Stifel remains bullish on Disc Medicine stock despite potential FDA delay - Investing.com Canada
Morgan Stanley Reaffirms Positive Outlook on IRON Despite FDA Re - GuruFocus
Disc Medicine (NASDAQ:IRON) Shares Gap DownShould You Sell? - MarketBeat
Experimental drug suspended❓💊 Shares od Disc Medicine lose as much as 7% 🚨 - XTB.com
Disc Medicine (IRON) Shares Decline as FDA Review Faces Brief De - GuruFocus
Fda pushes back review of Sanofi's diabetes drug Tzield and Disc Medicine's blood disorder drug -documents - marketscreener.com
How Disc Medicine’s New HR Chief and Bitopertin Review Could Shape IRON’s Commercial Readiness - Sahm
Disc Medicine, Inc. (NASDAQ:IRON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Aug Gainers: Should I hold or sell Disc Medicine Inc stock in 2025July 2025 WrapUp & Stepwise Entry/Exit Trade Alerts - Bộ Nội Vụ
Is Disc Medicine (IRON) Offering An Opportunity After Recent Volatility And DCF Valuation Gap - Yahoo Finance
Disc Medicine appoints Lisa Amaya Price as chief human resources officer - Investing.com Nigeria
Disc Medicine outlines 2026 pipeline priorities after NDA submission By Investing.com - Investing.com Nigeria
Disc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - citybiz
Disc Medicine (IRON) Appoints New Chief Human Resources Officer - GuruFocus
News | decaturdailydemocrat.comDisc Medicine Appoints Lisa Amaya Price, MBA as Chief Human Resources Officer - FinancialContent
Disc Medicine (IRON) Shares Strategic Goals and Pipeline Developments for 2026 - GuruFocus
Disc Medicine outlines 2026 pipeline priorities after NDA submission - Investing.com
Disc Medicine prepares for potential 2026 bitopertin FDA decision - TipRanks
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026 - The Manila Times
FDA weighs new blood disorder drug as small biotech sets a pivotal 2026 - Stock Titan
The Technical Signals Behind (IRON) That Institutions Follow - Stock Traders Daily
Disc Medicine Inc Appoints Lisa Amaya Price as Chief Human Resources Officer - marketscreener.com
Finanzdaten der Disc Medicine Inc-Aktie (IRON)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):